A dual mechanism linking NGF/ProNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 5, 2011, Pages 635-647

  Capsoni, S ^b   Brandi, R ^a   Arisi, I ^a   D'Onofri, M ^a   Cattaneo, A ^a,b  

^a EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^b SCUOLA NORMALE SUPERIORE   (Italy)

Author keywords

Alzheimer's disease; Antibody; Knockout; Mouse model; Neuroantibody approach; NGF; Prongf

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMYLOID BETA PROTEIN; CD47 ANTIGEN; CD72 ANTIGEN; CYCLOOXYGENASE 2; DONEPEZIL; GALANTAMINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MEMANTINE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NEUROTROPHIC FACTOR; RANTES; SORTILIN; STEM CELL FACTOR RECEPTOR; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; BASAL FOREBRAIN CHOLINERGIC NEURON; CELL DEATH; CELL SURVIVAL; CELL TRANSPORT; DENTATE GYRUS; DISEASE MODEL; DRUG SCREENING; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; MEMORY DISORDER; MENTAL FUNCTION; NERVE CELL; NERVE CELL NETWORK; NERVE DEGENERATION; NERVE EXCITABILITY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WORKING MEMORY;

EID: 79959985280     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711796235032     Document Type: Article

References (109)

1. rd.; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-414.
2. Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; Delon, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982, 215, 1237-1239.
3. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
4. Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak-Vance, M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991, 349, 704-706.
5. Levy-Lahad, E.; Wasco, W.; Poorkaj, P.; Romano, D.M.; Oshima, J.; Pettingell, W.H.; Yu, C.E.; Jondro, P.D.; Schmidt, S.D.; Wang, K.; Crowley, A.C.; Fu, Y.-H.; Guenette, S.Y.; Galas, D.; Nemens, E.; Wijsman, E.M.; Bird, T.D.; Schellenberg, G.D.; Tanzi, R.E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, 1995, 269, 973-977.
6. Rogaev, E.I.; Sherrington, R.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Liang, Y.; Chi, H.; Lin, C.; Holman, K.; Tsuda, T.; Mar, L.; Sorbi, S.; Nacmias, B.; Placentini, S.; Amaducci, L.; Chumakov, I.; Cohen, D.; Lannfelt, L.; Fraser, P.E.; Rommens, J.M.; St. George-Hyslop, P.H. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature, 1995, 376, 775-778.
7. Sherrington, R.; Rogaev, E.I.; Liang, Y.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Chi, H.; Lin, C.; Li, G.; Holman, K.; Tsuda, T.; Mar, L.; Foncin, J.F.; Bruni, A.C.; Montesi, M.P.; Sorbi, S.; Rainero, I.; Pinessi, L.; Nee, L.; Chumakov, I.; Pollen, D.; Brookes, A.; Sanseau, P.; Polinsky, R.J.; Wasco, W.; Da Silva, H.A.; Haines, J.L.; Perkicak-Vance, M.A.; Tanzi, R.E.; Roses, A.D.; Fraser, P.E.; Rommens, J.M.; St George-Hyslop, P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 1995, 375, 754-760.
8. Sahara, N.; Lewis, J.; DeTure, M.; McGowan, E.; Dickson, D.W.; Hutton, M.; Yen, S.H. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem., 2002, 83, 1498-1508.
9. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356.
10. Tanzi, R.E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 2005, 120, 545-555.
11. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
12. St George-Hyslop, P.H.; Morris, J.C. Will anti-amyloid therapies work for Alzheimer's disease? Lancet, 2008, 372, 180-182.
13. Salloway, S. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 2009, 73, 2061-2070.
14. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science, 2002, 298, 789-791.
15. Small, S.A.; Duff, K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron, 2008, 60, 534-542.
16. Cassel, J.C.; Mathis, C.; Majchrzak, M.; Moreau, P.H.; Dalrymple-Alford, J.C. Coexisting cholinergic and parahippocampal degeneration: a key to memory loss in dementia and a challenge for transgenic models? Neurodegener. Dis., 2008, 5, 304-317.
17. Zhas, K.R.; Ashe, K.H. Too much good news - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci., 2010, 33, 31-38.
18. Ashe, K.H.; Zahs, K.R. Probing the biology of Alzheimer's disease in mice. Neuron, 2010, 66, 631-645.
19. do, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39, 409-421.
20. Ruberti, F.; Capsoni, S.; Comparini, A.; Di Daniel, E.; Franzot, J.; Gonfloni, S.; Rossi, G.; Berardi, N.; Cattaneo, A. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci., 2000, 20, 2589-2601.
21. Piccioli, P.; di Luzio, A.; Amann, R.; Schuligoi, R.; Surani, M.A.; Donnerer, J.; Cattaneo, A. Neuroantibodies: ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice. Neuron, 1995, 15, 373-384.
22. Smeyne, R.J.; Klein, R.; Schnapp, A.; Long, L.K.; Bryant, S.; Lewin, A.; Lira, S.A.; Barbacid, M. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature, 1994, 368, 246-249.
23. Crowley, C.; Spencer, S.D.; Nishimura, M.C.; Chen, K.S.; Pitts-Meek, S.; Armanini, M.P.; Ling, L.H.; McMahon, S.B.; Shelton, D.L.; Levinson, A.D.; Phillips, S.H. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell, 1994, 76, 1001-1011.
24. Chen, K.S.; Nishimura, M.C.; Armanini, M.P.; Crowley, C.; Spencer, S.D.; Phillips, H.S. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J. Neurosci., 1997, 17, 7288-7296.
25. Levi-Montalcini, R. Effects of mouse tumor transplantation on the nervous system. Ann. NY Acad. Sci., 1952, 55, 330-344.
26. Levi-Montalcini, R. The nerve growth factor 35 years later. Science, 1987, 237, 1154-1162.
27. Hefti, F.; Weiner, W.J. Nerve growth factor and Alzheimer's disease. Ann. Neurol., 1986, 20, 275-281.
28. Mufson, E.J.; Kroin, J.S.; Sendera, T.J.; Sobreviela, T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol., 1999, 57, 451-484.
29. Ebendal, T. NGF in CNS: experimental data and clinical implications. Prog. Growth Factor Res., 1989, 1, 143-159.
30. Phelps, C.H.; Gage, F.H.; Growdon, J.H.; Hefti, F.; Harbaugh, R.; Johnston, M.V.; Khachaturian, Z.S.; Mobley, W.C.; Price, D.L.; Raskind, M.; Simpkins, J.; Thal, L.J.; Woodcock, J. Potential use of nerve growth factor to treat Alzheimer's disease. Neurobiol. Aging, 1989, 10, 205-207.
31. Counts, S.E.; Nadeem, M.; Wuu, J.; Ginsberg, S.D.; Saragovi, H.U.; Mufson, E.J. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann. Neurol., 2004, 56, 520-531.
32. Mufson, E.J.; Ma, S.Y.; Cochran, E.J.; Bennett, D.A.; Beckett, L.A.; Jaffar, S.; Saragovi, H.U.; Kordower, J.H. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol., 2000, 427, 19-30.
33. Fahnestock, M.; Michalski, B.; Xu, B.; Coughlin, M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell Neurosci., 2001, 18, 210-220.
34. St Amand, D.; Pottage, C.; Henry, P.; Fahnestock, M. Method for quantitation of low-abundance nerve growth factor mRNA expression in human nervous tissue using competitive reverse transcription polymerase chain reaction. DNA Cell Biol., 1996, 15, 415-422.
35. Salehi, A.; Delcroix, J.D.; Mobley, W.C. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci., 2003, 26, 73-80.
36. Schindowski, K.; Belarbi, K.; Buee, L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav., 2008, 7(Suppl 1), 43-56.
37. Lee, R.; Kermani, P.; Teng, K.K.; Hempstead, B.L. Regulation of cell survival by secreted proneurotrophins. Science, 2001, 294, 1945-1948.
38. Shooter, E.M. Early days of the nerve growth factor proteins. Annu. Rev. Neurosci., 2001, 24, 601-629.
39. Bruno, M.A.; Cuello, A.C. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. USA, 2006, 103, 6735-6740.
40. Fahnestock, M.; Yu, G.; Coughlin, M.D. ProNGF: a neurotrophic or an apoptotic molecule? Prog. Brain Res., 2004, 146, 101-110.
41. Counts, S.E.; Mufson, E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol., 2005, 64, 263-272.
42. Nykjaer, A.; Lee, R.; Teng, K.K.; Jansen, P.; Madsen, P.; Nielsen, M.S.; Jacobsen, C.; Kliemannel, M.; Schwarz, E.; Willnow, T.E.; Hempstead, B.L.; Petersen, CM. Sortilin is essential for proNGF-induced neuronal cell death. Nature, 2004, 427, 843-848.
43. Muhammad, A.; Flores, I.; Zhang, H.; Yu, R.; Staniszewski, A.; Planel, E.; Herman, M.; Ho, L.; Kreber, R.; Honig, L.S.; Ganetzky, B.; Duff, K.; Arancio, O.; Small, S.A. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Ap accumulation. Proc. Natl. Acad. Sci. USA, 2008, 105, 7327-7332.
44. Bruno, M.A.; Leon, W.C.; Fragoso, G.; Mushynski, W.E.; Almazan, G.; Cuello, A.C. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J. Neuropathol. Exp. Neurol, 2009, 68, 857-869.
45. Nykjaer, A.; Willnow, T.E.; Petersen, CM. p75NTR--live or let die. Curr. Opin. Neurobiol, 2005, 15, 49-57.
46. Hempstead, B.L. Dissecting the diverse actions of pro- and mature neurotrophins. Curr. Alzheimer Res., 2006, 3, 19-24.
47. Matrone, C; Ciotti, M.T.; Mercanti, D.; Marolda, R.; Calissano, P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc. Natl. Acad. Sci. USA, 2008, 105, 13139-13144.
48. Matrone, C; Di Luzio, A.; Meli, G.; D'Aguanno, S.; Severini, C; Ciotti, M.T.; Cattaneo, A.; Calissano, P. Activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells. J. Alzheimers Dis., 2008, 13, 81-96.
49. Tan, J.; Town, T.; Placzek, A.; Kundtz, A.; Yu, H.; Mullan, M. Bcl-X(L) inhibits apoptosis and necrosis produced by Alzheimer's beta-amyloid1-40 peptide in PC12 cells. Neurosci. Lett., 1999, 272, 5-8.
50. Berardi, N.; Braschi, C; Capsoni, S.; Cattaneo, A.; Maffei, L. Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. J. Alzheimers Dis., 2007, 11, 359-370.
51. De Rosa, R.; Garcia, A.A.; Braschi, C; Capsoni, S.; Maffei, L.; Berardi, N.; Cattaneo, A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD 11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. USA, 2005, 102, 3811-3816.
52. Origlia, N.; Capsoni, S.; Domenici, L.; Cattaneo, A. Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice. J. Alzheimers Dis., 2006, 9, 59-68.
53. Sola, E.; Capsoni, S.; Rosato-Siri, M.; Cattaneo, A.; Cherubini, E. Failure of nicotine-dependent enhancement of synaptic efficacy at Schaffer-collateral CA1 synapses of AD11 anti-nerve growth factor transgenic mice. Eur. J. Neurosci., 2006, 24, 1252-1264.
54. Capsoni, S.; Giannotta, S.; Cattaneo, A. Early events in Alzheimerlike neurodegeneration in anti-nerve growth factor trangenic mice. Brain Aging, 2002, 2(4), 24-43.
55. Corsetti, V.; Amadoro, G.; Gentile, A.; Capsoni, S.; Ciotti, M.T.; Cencioni, M.T.; Atlante, A.; Canu, N.; Rohn, T.T.; Cattaneo, A.; Calissano, P. Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models. Mol. Cell Neurosci., 2008, 38, 381-392.
56. Capsoni, S.; Giannotta, S.; Cattaneo, A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA, 2002, 99, 12432-12437.
57. Berardi, N.; Braschi, C; Capsoni, S.; Poli, A.; Cattaneo, A.; Maffei, L. BDNF Intranasal Administration Rescues Visual Memory Deficits in a Mouse Model of Alzheimer Disease (AD), The AD11 Mouse. In: Abstract 217.3, 6th Forum of European Neuroscience (FENS), July 12-16, Geneva, Switzerland, 2008.
58. Capsoni, S.; Giannotta, S.; Stebel, M.; Garcia, A.A.; De Rosa, R.; Villetti, G.; Imbimbo, B.P.; Pietra, C; Cattaneo, A. Ganstigmine and donepezil improve neurodegeneration in AD 11 antinerve growth factor transgenic mice. Am. J. Alzheimers Dis. Other Demen., 2004, 19, 153-160.
59. Psoni, S.; De Rosa, R.; Margotti, E.; Cattaneo, A. Effects of Combination Treatment of Galantamine and Memantine on AD 11 anti-NGF Mice. In: Abstrtact, 10th International Congress on Alzheimer's Disease and related disorders, July 15-20, Madrid, 2006.
60. Van Dam, D.; De Deyn, P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur. Neuropsychopharmacol, 2006, 16, 59-69.
61. Van Dam, D.; Abramowski, D.; Staufenbiel, M.; De Deyn, P.P. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl.), 2005, 180, 177-190.
62. Dong, H.; Yuede, C.M.; Coughlan, C.A.; Murphy, K.M.; Csernansky, J.G. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res., 2009, 1303, 169-178.
63. Dong, H.; Csernansky, C.A.; Martin, M.V.; Bertchume, A.; Vallera, D.; Csernansky, J.G. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl.), 2005, 181, 145-152.
64. Dong, H.; Yuede, C.M.; Coughlan, C.; Lewis, B.; Csernansky, J.G. Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology, 2008, 33, 3226-3236.
65. Scholtzova, H.; Wadghiri, Y.Z.; Douadi, M.; Sigurdsson, E.M.; Li, Y.S.; Quartermain, D.; Banerjee, P.; Wisniewski, T. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J. Neurosci. Res., 2008, 86, 2784-2791.
66. Martinez-Coria, H.; Green, K.N.; Billings, L.M.; Kitazawa, M.; Albrecht, M.; Rammes, G.; Parsons, C.G.; Gupta, S.; Banerjee, P.; LaFerla, F.M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am. J. Pathol., 2010, 176, 870-880.
67. Minkeviciene, R.; Banerjee, P.; Tanila, H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther., 2004, 311, 677-682.
68. Rosato-Siri, M.; Cattaneo, A.; Cherubini, E. Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. J. Physiol., 2006, 576, 361-377.
69. Lagostena, L.; Rosato-Siri, M.; D'Onofrio, M.; Brandi, R.; Arisi, I.; Capsoni, S.; Franzot, J.; Cattaneo, A.; Cherubini, E. In the adult hippocampus, chronic nerve growth factor deprivation shifts GABAergic signaling from the hyperpolarizing to the depolarizing direction. J. Neurosci., 2010, 30, 885-893.
70. Blaesse, P; Airaksinen, M.S; Rivera, C; Kaila, K. Cation-chloride cotransporters and neuronal function. Neuron, 2009, 61, 820-838.
71. Palop, J.J.; Chin, J.; Mucke, L. A network dysfunction perspective on eurodegenerative diseases. Nature, 2006, 443, 768-773.
72. Palop, J.J.; Chin, J.; Roberson, E.D.; Wang, J.; Thwin, M.T.; Bien-Ly, N.; Yoo, J.; Ho, K.O.; Yu, G.Q.; Kreitzer, A.; Finkbeiner, S.; Noebels, J.L.; Mucke, L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, 55, 697-711.
73. Houeland, G.; Romani A.; Marchetti C.; Amato G.; Capsoni S.; Cattaneo A.; Marie H. Transgenic Mice with Chronic NGF Deprivation and Alzheimer's Disease-Like Pathology Display Hippocampal Region-Specific Impairments in Short- and Long-Term Plasticities. J. Neurosci., 2010, 30, 13089-13094.
74. Rogaeva, E.; Meng, Y.; Lee, J.H.; Gu, Y.; Kawarai, T.; Zou, F.; Katayama, T.; Baldwin, C.T.; Cheng, R.; Hasegawa, H.; Chen, F.; Shibata, N.; Lunetta, K.L.; Pardossi-Piquard, R.; Bohm, C.; Wakutani, Y.; Cupples, L.A.; Cuenco, K.T.; Green, R.C.; Pinessi, L.; Rainero, I.; Sorbi, S.; Bruni, A.; Duara, R.; Friedland, R.P.; Inzelberg, R.; Hampe, W.; Bujo, H.; Song, Y.Q.; Andersen, O.M.; Willnow, T.E.; Graff-Radford, N.; Petersen, R.C.; Dickson, D.; Der, S.D.; Fraser, P.E.; Schmitt-Ulms, G.; Younkin, S.; Mayeux, R.; Farrer, L.A.; St George-Hyslop, P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet, 2007, 39, 168-177.
75. Dyrks, T.; Dyrks, E.; Masters, C.L.; Beyreuther, K. Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett., 1993, 324, 231-236.
76. Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C.L.; Beyreuther, K. Human and rodent sequence analogs of Alzheimer's amyloid beta A4 share similar properties and can be solubilized in buffers of pH 7.4. Eur. J. Biochem., 1991, 201, 61-69.
77. Dolev, I.; Michaelson, D.M. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. USA, 2004, 101, 13909-13914.
78. Del Valle, J.; Duran-Vilaregut, J.; Manich, G.; Casadesús, G.; Smith, M.A.; Camins, A.; Pallàs, M.; Pelegrí, C.J.V. Early Amyloid Accumulation in the Hippocampus of SAMP8 Mice. J. Alzheimer Dis., 2010, 19, 1303-1315.
79. Covaceuszach, S.; Cassetta, A.; Konarev, P.V.; Gonfloni, S.; Rudolph, R.; Svergun, D.I.; Lamba, D.; Cattaneo, A. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody. J. Mol. Biol., 2008, 381, 881-896.
80. Capsoni, S.; Cattaneo, A. On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. Cell Mol. Neurobiol., 2006, 26, 619-633.
81. Matrone, C.; Marolda, R.; Ciafre, S.; Ciotti, M.T.; Mercanti, D.; Calissano, P. Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation. Proc. Natl. Acad. Sci. USA, 2009, 106, 11358-11363.
82. Nikolaev, A.; McLaughlin, T.; O'Leary, D.D.; Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature, 2009, 457, 981-989.
83. Capsoni, S.; Tiveron, C.; Vignone, D.; Amato, G.; Cattaneo, A. Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Proc. Natl. Acad. Sci. USA, 2010, 107, 12299-12304.
84. Cattaneo, A.; Capsoni, S.; Margotti, E.; Righi, M.; Kontsekova, E.; Pavlik, P.; Filipcik, P.; Novak, M. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J. Neurosci., 1999, 19, 9687-9697.
85. Covaceuszach, S.; Cattaneo, A.; Lamba, D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Proteins, 2005, 58, 717-727.
86. Ugolini, G.; Marinelli, S.; Covaceuszach, S.; Cattaneo, A.; Pavone, F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc. Natl. Acad. Sci. USA, 2007, 104, 2985-2990.
87. Lee, K.F.; Li, E.; Huber, L.J.; Landis, S.C.; Sharpe, A.H.; Chao, M.V.; Jaenisch, R. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell, 1992, 69, 737-749.
88. Capsoni, S.; Tiveron, C.; Amato, G.; Vignone, D.; Cattaneo, A. Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice. J. Alzheimers Dis., 2010, 20, 527-546.
89. Edvinsson, L.; Hardebo, J.E.; Owman, C. Influence of the cerebrovascular sympathetic innervation on regional flow, autoregulation, and blood-brain barrier function. Ciba Found. Symp., 1978, 69-95.
90. Heistad, D.D. Protection of the blood-brain barrier during acute and chronic hypertension. Fed. Proc., 1984, 43, 205-209.
91. D'Andrea, M.R. Evidence linking autoimmunity to neuronal cell death in Alzheimer's disease. Brain Res., 2003, 982, 19-30.
92. D'Andrea, M.R. Add Alzheimer's disease to the list of autoimmune diseases. Med. Hypotheses, 2005, 64, 458-463.
93. Okovic, B.V. Blood-brain barrier in health and chronic neurodegenerative disorders. Neuron Neuron, 2008, 57, 178-1201.
94. Zlokovic, B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol, 2009, 118, 103-113.
95. Dicou, E.; Nerriere, V. Evidence that natural autoantibodies against the nerve growth factor (NGF) may be potential carriers of NGF. J. Neuroimmunol, 1997, 75, 200-203.
96. Marksteiner, J.; Pirchl, M.; Ullrich, C; Oberbauer, H.; Blasko, I.; Lederer, W.; Hinterhuber, H.; Humpel, C. Analysis of cerebrospinal fluid of Alzheimer patients.Biomarkers and toxic properties. Pharmacology, 2008, 82, 214-220.
97. Watts, H.; Kennedy, P.G.; Thomas, M. The significance of antineuronal antibodies in Alzheimer's disease. J. Neuroimmunol, 1981, 1, 107-116.
98. Leonardi, A.; Gandolfo, C; Caponnetto, C; Arata, L.; Vecchia, R. The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J. Neurol. Sci., 1985, 67, 253- 261.
99. Angeletti, P.U.; Levi-Montalcini, R.; Caramia, F. Analysis of the effects of the antiserum to the nerve growth factor in adult mice. Brain Res., 1971, 27, 343-355.
100. Levi-Montalcini, R.; Booker, B. Excessive Growth of the Sympathetic Ganglia Evoked by a Protein Isolated from Mouse Salivary Glands. Proc. Natl. Acad. Sci. USA, 1960, 46, 384-391.
101. Ruit, K.G.; Osborne, P.A.; Schmidt, R.E.; Johnson, E.M., Jr.; Snider, W.D. Nerve growth factor regulates sympathetic ganglion cell morphology and survival in the adult mouse. J. Neurosci., 1990, 10, 2412-2419.
102. D'Onofrio, M.; Arisi, I.; Brandi, R.; Di Mambro, A.; Felsani, A.; Zhas, C; Cattaneo, A. Early inflammation and immune response mRNAs in the brain of AD11 anti-NGF mice. Neurobiol. Aging, 2010, doi:10.1016/j.neurobiolaging.2009.05.023.
103. Parachikova, A.; Agadjanyan, M.G.; Cribbs, D.H.; Blurton-Jones, M.; Perreau, V.; Rogers, J.; Beach, T.G.; Cotman, C.W. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging, 2007, 28, 1821-1833.
104. Stevens, B.; Allen, N.J.; Vazquez, L.E.; Howell, G.R.; Christopherson, K.S.; Nouri, N.; Micheva, K.D.; Mehalow, A.K.; Huberman, A.D.; Stafford, B.; Sher, A.; Litke, A.M.; Lambris, J.D.; Smith, S.J.; John, S.W.; Barres, B.A. The classical complement cascade mediates CNS synapse elimination. Cell, 2007, 131, 1164-1178.
105. Boulanger, L.M.; Shatz, C.J. Immune signalling in neural development, synaptic plasticity and disease. Nat. Rev. Neurosci., 2004, 5, 521-531.
106. Ray, S.; Britschgi, M.; Herbert, C; Takeda-Uchimura, Y.; Boxer, A.; Blennow, K.; Friedman, L.F.; Galasko, D.R.; Jutel, M.; Karydas, A.; Kaye, J.A.; Leszek, J.; Miller, B.L.; Minthon, L.; Quinn, J.F.; Rabinovici, G.D.; Robinson, W.H.; Sabbagh, M.N.; So, Y.T.; Sparks, D.L.; Tabaton, M.; Tinklenberg, J.; Yesavage, J.A.; Tibshirani, R.; Wyss-Coray, T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med., 2007, 13, 1359-1362.
107. Perry, V.H.; Nicoll, J.A.; Holmes, C. Microglia in neurodegenerative disease. Nat. Rev. Neurol., 2010, 6, 193-201.
108. Perry, V.H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol., 2010, 120, 277-286.
109. Perry, V.H.; O'Connor, V. C1q: the perfect complement for a synaptic feast? Nat. Rev. Neurosci., 2008, 9, 807-811.